Important Reminders

This presentation may include forward-looking statements pertaining to the business and prospects of Chugai Pharmaceutical Co., Ltd. (the “Company”). These statements reflect the Company’s current analysis of existing information and trends. Actual results may differ from expectations based on risks and uncertainties that may affect the Company’s businesses.

Information regarding pharmaceuticals (including products under development) is included in this presentation, but is not intended as advertising or medical advice.
Outline of the Presentation

Chugai ESG Meeting 2019

Chugai’s Value Creation

IBI 21 and ESG Initiatives

Looking Ahead
Chugai’s Value Creation
Since the Company’s founding, Chugai has maintained a dedication to working for the benefit of patients and human health, while changing its business model in response to the changing expectations and needs of society and patients.
Mission Statement

Mission
Dedicate ourselves to adding value by creating and delivering innovative products and services for the medical community and human health around the world

Core Values
1. Patient Centric
Make each patient’s wellbeing our highest priority

2. Pioneering Spirit
Pursue innovation by improving ourselves and thinking differently

3. Integrity
Maintain the highest standards in all we do to create shared value with society

Envisioned Future
Become a top innovator for advanced and sustainable patient-centric healthcare, powered by our unique strengths in science and technology and the alliance with Roche
Background of Formulation of the Basic Policy

**Will**
- Bring true value to patients

**Must**
- Fulfill our obligations as a top pharmaceutical company
  - Build a sustainable healthcare framework
  - Tirelessly pursue quality in every function

**Can**
- Focus on science- and technology-based innovation
  - Further innovate our unique strengths and technologies
  - Take full advantage of cooperation with Roche
Basic Policy (Envisioned Future)

Become a top innovator for advanced and sustainable patient-centric healthcare, powered by our unique strengths in science and technology and the alliance with Roche.

- **Chugai growth and development**
  - Increased corporate value
  - **Creation of value shared by Chugai and Society**
    - Realize advanced and sustainable patient-centric healthcare
  - **Focus on innovation**
    - Creation of innovative drugs and services
    - **Strategic alliance with Roche**
    - **Chugai’s unique science and technologies**
  - **Chugai business model adopted**

- **Social growth and development**
  - Resolution of social issues
Creation of Shared Value with Stakeholders

Families of patients
- Burden reduction

Patients
- Better drug efficacy and safety
- Better QoL
- Treatment choices that fit each patient

Countries
- Growth of the healthcare industry
- Improvement of fiscal balance

Communities
- Advanced and sustainable community-based care
- Improvement of local government finances

Healthcare providers and medical institutions
- Better disease control
- More treatment options

Shareholders and investors
- Higher added value
- Increased profits

Suppliers and wholesalers, etc.
- Economic stability and development

Universities and research companies/institutions
- Co-creation of innovation

Medical device manufacturers and healthcare companies
- Collaborative solutions

Employees
- Gain job satisfaction and sense of fulfillment
- Enhance abilities

Payers and regulators
- Sustainable healthcare financing
- Appropriate spending levels

Countries
- Growth of the healthcare industry
- Improvement of fiscal balance

Communities
- Advanced and sustainable community-based care
- Improvement of local government finances

Healthcare providers and medical institutions
- Better disease control
- More treatment options

Shareholders and investors
- Higher added value
- Increased profits

Suppliers and wholesalers, etc.
- Economic stability and development

Universities and research companies/institutions
- Co-creation of innovation

Employees
- Gain job satisfaction and sense of fulfillment
- Enhance abilities

Payers and regulators
- Sustainable healthcare financing
- Appropriate spending levels
Process for Establishing Material Issues

We analyzed the future market environment, referred to the SDGs, GRI, SASB and other frameworks, and comprehensively identified the issues that society expects Chugai to address. We also scrutinized items for which Chugai is not sufficiently meeting expectations. After an objective analysis that incorporated outside views, we narrowed the list of issues to those for realizing Chugai's Envisioned Future. Based on that process, we specified 25 material issues in eight categories.

**STEP 1** Analysis of mid- to long-term conditions and identification of risks and opportunities

**STEP 2** Discussion of management policies (Executive Committee)

**STEP 3** Interviews of outside experts

**STEP 4** Gap analysis (requests from outside stakeholders, comparison with other companies)

**STEP 5** Analysis of social issues we want to solve (value) and material issues

**STEP 6** Consultation with internal divisions

**STEP 7** Specification of material issues (Outside directors, Executive Committee, Board of Directors)
Material Issues

Chugai’s impact on the economy, society and environment

Most important

- Corporate governance
- Risk management
- Compliance
- Disclosure and engagement
- Code of conduct
- Employee job satisfaction
- Human rights
- Climate change countermeasures
- Use of renewable/recycled resources

Important

- Fair transactions
- Supply chain management
- Improvement of occupational health and safety
- Social contribution activities
- Protection of biodiversity
- Environmental management system

Stakeholder interest

Most important

- Creation of innovative drugs and services
- Provision of solutions for patients
- Fair marketing
- Adverse event management
- Safety of clinical trial subjects
- Quality assurance and stable supply of products
- Improvement of access to healthcare

- Development of employee potential
- Diversity and inclusion
- Fair pricing
IBI 21 and ESG Initiatives
Overview of Mid-term Business Plan IBI 21

Accelerate corporate and social development through innovation focused on innovative products

Create Global Growth Drivers and Maximize Value

- **Value Creation**
  - Strategy 1: Realize innovative drug discovery to cure and manage diseases

- **Value Delivery**
  - Strategy 2: Deliver patient-centric solution to maximize value of growth drivers

Promote Advances in Personalized Healthcare (PHC)
- Strategy 3: Realize the further advancement of PHC and innovate R&D process by utilizing digital technology and data

Strengthen HR and Infrastructure That Support Chugai’s Business

- **Strengthen Human Capital and Conduct Fundamental Structural Reform**
  - Strategy 4: Develop high-caliber HR talent that supports innovation, and thoroughly reform costs, systems and processes

- **Strengthen Sustainable Platforms**
  - Strategy 5: Simultaneously realize company growth and sustainable social development
Strategy 5: Strengthen Sustainable Platforms

Corporate Value = Economic Value + Social Value

Supply chain management
Quality management
Healthcare access
Stakeholder engagement
Global environment
Social contribution

Strengthening sustainable platforms will support our pursuit of innovation
Strategy 5: Strengthen Sustainable Platforms

Quality management
- Maintain and enhance world-class level of quality
- Foster and instill a quality culture

Supply chain management
- Strengthen supplier management (human rights, consideration for the environment, etc.)
- Conduct supplier due diligence

Healthcare access
- Contribute to global health
Strategy 5: Strengthen Sustainable Platforms ②

Social contribution
• Contribute to medical care, welfare, social inclusion, support for the next generation, and communities

Global environment
• Implement measures to combat climate change
• Use recycled/renewable resources
• Contribute to protection of biodiversity
• Take measures to preserve water resources and mitigate water risk

Stakeholder engagement
• Promote engagement with stakeholders
• Strengthen information disclosure and dissemination
Supply Chain Management: Main Points

In addition to ensuring stable supplies and preserving quality, changes in society and the environment make it essential for management to enhance social value with suppliers.

We have strengthened our supplier evaluation to help realize sustainable supply chain management that supports continuous innovation and creation of a sustainable society.

Establishment of a Comprehensive Evaluation System for Suppliers

- Finance
- Supply
- Quality
- Contracts
- Intellectual property security
- EHS compliance

Build a structure for comprehensive evaluation of risk assessments in each category

Decide whether to do business with the supplier

* EHS & compliance: Supplier’s responsibility in ethics, labor, health and safety, and the environment (including child labor, forced labor and other human rights issues)
## Supplier EHS & Compliance Evaluation

### 2021 Goals

<table>
<thead>
<tr>
<th>Year</th>
<th>Goal Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dec. 2017</td>
<td>Began anti-corruption due diligence</td>
</tr>
<tr>
<td>Sep. 2018</td>
<td>Conducted dialogues with experts on human rights policy</td>
</tr>
<tr>
<td>Nov. 2018</td>
<td>Joined the Pharmaceutical Supply Chain Initiative (PSCI)</td>
</tr>
<tr>
<td>Jan. 2019</td>
<td>Formulated and announced our human rights policy</td>
</tr>
<tr>
<td>2019～</td>
<td>Plan to begin evaluation of supplier EHS &amp; compliance</td>
</tr>
</tbody>
</table>

### Proposed 2030 Goal

Conduct evaluations of secondary suppliers of major suppliers

### Three-Year Milestones

<table>
<thead>
<tr>
<th>Year</th>
<th>Milestones</th>
</tr>
</thead>
<tbody>
<tr>
<td>2019</td>
<td>• Formulation of human rights policy</td>
</tr>
<tr>
<td></td>
<td>• Formulation of guidelines for EHS &amp; compliance risk assessment</td>
</tr>
<tr>
<td>2020</td>
<td>• Assessment of EHS compliance risk</td>
</tr>
<tr>
<td></td>
<td>• Supplier briefings</td>
</tr>
<tr>
<td>2021</td>
<td>• Education of employees</td>
</tr>
</tbody>
</table>
Global Environment: Overview of Strategy

Based on the requirements of the Paris Agreement, we examined priority issues in the value chain overall, and set next-fiscal year environmental goals for the following items in 2019. We are beginning to consider measures for CDP evaluation improvements and initiatives consistent with TCFD recommendations.

<table>
<thead>
<tr>
<th>Priority Themes in Mid-term Business Plan</th>
<th>Items</th>
<th>2020 KPIs</th>
<th>Considering as 2025-2030 KPIs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Climate change countermeasures (Prevention of global warming)</td>
<td>Energy consumption</td>
<td>✓</td>
<td>20% reduction (GJ per employee)</td>
</tr>
<tr>
<td></td>
<td>CO₂ emissions</td>
<td>✓</td>
<td>Avg. fuel efficiency of MR fleet: 16 km/L or higher</td>
</tr>
<tr>
<td></td>
<td>Renewable energy usage rate</td>
<td>✓</td>
<td>—</td>
</tr>
<tr>
<td></td>
<td>Use of CFCs</td>
<td>✓</td>
<td>—</td>
</tr>
<tr>
<td></td>
<td>Scope 3 (flight, waste, etc.)</td>
<td>✓</td>
<td>—</td>
</tr>
<tr>
<td>Resource conservation/ Waste management</td>
<td>Waste recycling ratio</td>
<td>✓</td>
<td>99% or higher at 3 or more sites</td>
</tr>
<tr>
<td></td>
<td>Volume of waste generated</td>
<td>✓</td>
<td>—</td>
</tr>
<tr>
<td></td>
<td>Water consumption</td>
<td>✓</td>
<td>—</td>
</tr>
<tr>
<td></td>
<td>Water recycling ratio</td>
<td>✓</td>
<td>—</td>
</tr>
<tr>
<td>Biodiversity protection (Reduction of environmental impact)</td>
<td>Prevention of pollution (air, water)</td>
<td>✓</td>
<td>Environmental impact assessment (WET testing)</td>
</tr>
<tr>
<td></td>
<td>Chemical substance management</td>
<td>✓</td>
<td>—</td>
</tr>
<tr>
<td></td>
<td>Environmental impact assessment</td>
<td>✓</td>
<td>—</td>
</tr>
<tr>
<td></td>
<td>Ecological footprint</td>
<td>✓</td>
<td>—</td>
</tr>
<tr>
<td>EHS management system</td>
<td>External assurance of non-financial information</td>
<td>✓</td>
<td>—</td>
</tr>
<tr>
<td></td>
<td>Supply chain management</td>
<td>✓</td>
<td>—</td>
</tr>
<tr>
<td></td>
<td>Training, internal/external audits</td>
<td>✓</td>
<td>—</td>
</tr>
</tbody>
</table>

✓ Items reported to Roche
Energy Consumption

2020 target: 20% reduction of energy consumption per employee vs. 2010

Total energy consumption in 2018 increased 11% from 2017 due to start of operation of UK3

Expect to achieve 2020 target for non-renewable energy consumption per employee by introducing electricity from renewable energy sources.
Specific Initiatives: Efforts at New Research Facility

**Chugai Life Science Park Yokohama**

A core research facility to be built in Yokohama, Kanagawa Prefecture (planned completion in 2022)

- **Building area:** 35,210m²
- **Total floor area:** 119,960m²

Emphasizing climate change measures, local disaster preparedness, and biodiversity preservation; aiming to acquire LEED Gold certification for environmental performance

Including consolidation of existing facilities, will reduce our overall environmental footprint

Sign environmental agreement with city of Yokohama, emphasizing coexistence with the local community

---

**Aiming for LEED Certification**

We are emphasizing climate change measures, local disaster preparedness and protection of biodiversity by introducing green infrastructure, and are aiming to acquire LEED Gold certification.

---

**Smaller Ecological Impact**

We plan to reduce our overall energy use, CO₂ emissions and waste by closing the Gotemba and Kamakura research centers and consolidating their functions and facilities.

**Coexistence**

Emphasizing coexistence with the local community and environment, we plan to create a park and recreation spot on the premises and cooperate with educational institutions.
Human Resource Initiatives: Main Points

**Talent management**
- Introduced a talent management system in 2012, and implemented it while making modifications as necessary
  - Globally unified competencies used in evaluation as the basis of talent management
  - Built CAPTAIN, a backbone system for HR management, and created a central database
  - Based on these, created development plans for each employee, and applied them in talent development
  - Built a talent pool for selection and visualization of successor candidates for 94 positions
- Will further review our HR requirements and development system to speed up recruiting, development and placement of world-class talent

**Diversity & inclusion (D&I)**
- Launched a working team in 2010 and set up specialized D&I unit in 2012
  - Focused on work environment improvements and career planning and development measures for female employees
  - Conducted diversity management training for managers
    - Ratio of female managers
      - 2018 target: 13% or higher, Actual: 13.3%
      - 2021 target: 16% or higher
  - Updated HR systems and conducted training to promote inclusion of older and foreign employees
- Drew up and will implement a detailed roadmap to foster an inclusive workplace culture where diverse employees can excel and pursue innovation

**Employee health management**
- Established a company-wide health and safety promotion framework to pursue both individual and organizational health
- Established and implemented measures to support employees with cancer, prevent/treat lifestyle diseases, promote employees’ mental health, address presentism, improve health literacy, and promote workplace safety
## Human Resource Initiatives: D&I Roadmap

### 2019
- Identify issues for fostering a culture that generates innovation
- Study measures and implement on a trial basis
- Promote personnel exchange within the Chugai Group and provide training opportunities
- Promote success of diverse talent by enhancing management capabilities

### 2020
- Review trials and fully introduce measures
- Identify and present innovation stories
- Implement measures for business process reform
- Promote work style reform by sharing best practices

### 2021
- Reinforce behavior that generates innovation
- Increase opportunities for employee growth and taking on challenges
- Work continuously to establish work style reform

### KPI
- **Employee Survey**
  - All-employee survey
  - Rate of affirmative answers to innovation questions
  - 80% or higher

### IBI21 Target Outcome
- Innovation stories that leverage the strengths of diversity and inclusion

### Work Style Reform
- Study and implement measures for changing mindset and behaviors
- Identify issues for business process reform
- Review and enhance systems, mechanisms, tools, workspaces, etc.

### Proactively appointing and deploying women and people from different cultures and backgrounds
- Create a system of divisional commitment to the success of women
- Identify issues, and study and implement measures to encourage the promotion of women
- Actively recruit, retain and create opportunities for promotion for people from different cultures and backgrounds

### Improving engagement of diverse talent (improving engagement through work style reform)
- Identify issues for improving engagement
- Study measures and implement on a trial basis

### Fostering an organizational culture that generates innovation and is accepting of failure
- Identify issues for fostering a culture that generates innovation
- Study measures and implement on a trial basis

### Business Process Reform
- Implement measures for business process reform
- Promote work style reform by sharing best practices
- Review and enhance systems, mechanisms, tools, workspaces, etc.

### All-employee survey
- Rate of affirmative answers to questions on engagement and stimulating workplace environment
- 80% or higher

### Ratio of female managers
- 16% or higher

---

* KPI set above the average for global companies

---

### Innovation stories
- Enhance approach to managers and employees to encourage the promotion of women
- Further expand the number of female leader candidates

---

### All-employee survey
- Rate of affirmative answers to questions on engagement and stimulating workplace environment
- 80% or higher

---

### Ratio of female managers
- 16% or higher (also set 3 other KPIs)
Human Resource Initiatives: Employee Survey

**Degree of Promotion of Strategies (All-employee survey results)**

(On a 5-point scale)

<table>
<thead>
<tr>
<th>Year</th>
<th>1.00</th>
<th>3.40</th>
<th>3.70</th>
<th>4.00</th>
<th>4.30</th>
</tr>
</thead>
<tbody>
<tr>
<td>2013</td>
<td>3.60</td>
<td>3.42</td>
<td>3.72</td>
<td>3.95</td>
<td>4.10</td>
</tr>
<tr>
<td>2014</td>
<td>3.72</td>
<td>3.67</td>
<td>3.96</td>
<td>4.18</td>
<td>4.30</td>
</tr>
<tr>
<td>2015</td>
<td>3.96</td>
<td>3.98</td>
<td>4.17</td>
<td>4.24</td>
<td></td>
</tr>
<tr>
<td>2016</td>
<td>3.95</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

(Initial year of IBI 18)

**Evaluation Item**

- I understand why it is necessary to achieve the targets of ACCEL 15/IBI 18 (Understanding)
- I am doing what I must to carry out ACCEL 15/IBI 18 (Action)
- My workplace has started to change for the better due to activities for ACCEL 15/IBI 18 (Realization)

Note: This survey was not conducted in 2017.

**Overview of Employee Survey (2018)**

| Participants and response rate | Participants: 6,994 (6,498 in Japan, 496 overseas) Respondents: 6,806 (6,321 in Japan, 485 overseas) Response rate: 97.3% |
| Question categories | Employee engagement, environment for utilizing employees, strategy and direction, leadership, quality and customer orientation, respect for individuals, opportunities for growth, compensation and benefits, performance indicators, authority and discretion, resources, education and training, framework for collaboration, business processes and organizational structure, and innovation |
| Benchmark data | Average results from global companies, leading companies, pharmaceutical companies and Japanese companies |

**Survey Results (Overall Trends)**

- In all question categories, Chugai scored above the average for Japanese companies. In Japan, Chugai is a leader in terms of employee awareness.
- Chugai is on par with global companies. Employee engagement is on par with top global companies.
- Issues for further improvement are the environment for utilizing employees, as well as the resources, framework for collaboration, and business processes and organizational structure that underlie that environment.
- The percentage of employees who gave employee engagement and working environment high marks is at the level of global companies.
Corporate Governance

Alliance Arrangement with Roche

- Roche acquires majority of Chugai’s shares (50.1%*)
- Chugai maintains management independence (TSE listing)

*Roche has owned 59.9% of Chugai’s shares since 2008

Composition of the Board of Directors

- Executive Directors: 3
- Non-Executive Directors: 3
- Independent Outside Directors: 3

Products in-licensed from Roche
- Exclusive domestic sales of breakthrough therapies
- Stable revenue base (Efficient product launches through collaboration with Roche)

Products from Chugai Research
- Able to specialize in highly innovative drug discovery
- Revenue base that drives growth (Out-licensing to Roche and global market development)
Corporate Governance Topics

Evaluation of Effectiveness of Board of Directors

January
Self-evaluation survey of all directors and Audit & Supervisory Board members

March
Analysis and evaluation by external experts

April
Board of Directors deliberates based on evaluation results

April
Board of Directors identifies items for improvement and considers methods for improvement

Status of Improvements Identified through Evaluation of the Effectiveness of the Board of Directors

<table>
<thead>
<tr>
<th>Year</th>
<th>Main Items for Improvement</th>
<th>Main New Initiatives Implemented after Analysis and Evaluation</th>
</tr>
</thead>
</table>
| 2016 | • Review structure of self-evaluation survey and answer options  
      • Assiduously provide materials for Board of Directors meetings at least four business days prior to the event  
      • Enhance content of reports provided to Board of Directors and make materials easily understood | • Began providing information on industry environment trends and other information to outside directors in a Chairman’s Message at the beginning of the Board of Directors meetings  
      • Provided Board of Directors meeting schedule for the coming year at an early date  
      • Implemented factory tours |
| 2017 | • Change the procedure for providing materials to outside officers  
      • Enhance topics for reports to the Board of Directors | • Held lectures (information on trends of general shareholders meetings) by external experts (attorneys) |
| 2018 | • Conduct prior and additional explanations on agenda items with complex content such as governance and legal matters | • Issued the Chugai IR Activities Report to outside officers (every quarter)  
      • Provided a glossary of technical terms, abbreviations etc. to outside officers |
Corporate Governance Topics ②

Chugai International Council (CIC)

- **CIC Chair**
  - Henry L. Nordhoff (U.S.)
    Former Chairman of the Board, Gen-Probe, Inc.

- **CIC Members**
  - Virginia Bottomley (U.K.)
    Former Health Secretary of the U.K.
  - William M. Burns (U.K.)
    Former Chief Executive Officer of the Pharmaceuticals Division, F. Hoffmann-La Roche Ltd.
  - Andrew von Eschenbach (U.S.)
    Former Commissioner of the U.S. Food and Drug Administration
  - Victor Halberstadt (Netherlands)
    Professor, Leiden University
  - Andre Hoffmann (Switzerland)
    Vice Chairman, Roche Holding Ltd.
  - Franz B. Humer (Switzerland)
    Former Chairman, Diageo plc
    Former Chairman, Roche Holding Ltd.
  - Robert A. Ingram (U.S.)
    Former Vice Chairman of Pharmaceuticals, GlaxoSmithKline plc
  - Arnold J. Levine (U.S.)
    Professor Emeritus at the Institute for Advanced Study, Princeton University
    Discoverer of the p53 cancer suppressor protein
  - Sonosuke Kadonaga (Japan)
    President, Intrinsics
Looking Ahead
Initiatives for the SDGs

**Goal 3**
Provision of innovative drugs and services/Provision of solutions for patients/Contribution to global health

**Goal 8**
Improvement of occupational health and safety/Talent management/Promotion of work-life synergy (promotion of use of childcare leave system by male employees and telecommuting system, etc.)/Supply chain management

**Goal 9**
Provision of innovative drugs and services/Initiatives for personalized healthcare/Establishment of open innovation networks with academia and other parties

**Goal 12**
Ensuring stable supply and stable inventories/Strengthening of quality assurance and stable supply/Use of renewable and recyclable resources/Environmental management

**Goal 17**
Establishment of open innovation networks/Stakeholder engagement strategy/Participation in GHIT Fund and Access Accelerated
Looking Ahead

Creation of Shared Value with Society

Realization of advanced and sustainable patient-centric healthcare
APPENDIX
PSCI (Pharmaceutical Supply Chain Initiative)

The PSCI is a non-profit organization established to improve sustainability among suppliers, buyers and society through standardization of guidelines for responsible procurement by pharmaceutical companies and creation of an information sharing platform for buyers.

- Established in 2006 in the U.S.
- Member companies: 30 (as of June 2018)
  * Roche is also a member
- Established industry principles that led to evaluation and improvement of suppliers sustainability
  - Supplier Win
- Results of supplier evaluations are shared with members, reducing the workload of buyers
  - Buyer Win

Triple win for society, buyers and suppliers

- ETHICS
- LABOR
- HEALTH & SAFETY
- ENVIRONMENT
- MANAGEMENT SYSTEMS
Activities with ESG Investment in Mind

- Reselection as Component of DJSI Asia Pacific Index -

Chugai is included in all ESG indices adopted by GPIF

Chugai continues to be selected for inclusion in global socially responsible investment indices

FTSE Blossom Japan

MSCI 2018 Constituent MSCI Japan ESG Select Leaders Index

MSCI Japan Empowering Women Index (WIN)

S&P/JPX Carbon Efficient Index

Chugai was selected for the fourth time as a component of the DJSI Asia Pacific Index, a socially responsible investment index

FTSE4Good
Stock Performance (From 2002)
- Relative change in stock price based on 9/30/2002 value fixed at 100 -

From 2017 onwards, stock prices are steadily rising mainly due to expectations for Hemlibra

* Stock Price: 9/30/02〜4/26/'19 * Closing price on 9/30/02 = 100
# Contacts: Corporate Communications Dept.

## Media Relations Group

<table>
<thead>
<tr>
<th>Tel:</th>
<th>+81 (0) 3-3273-0881</th>
</tr>
</thead>
<tbody>
<tr>
<td>E-mail:</td>
<td><a href="mailto:pr@chugai-pharm.co.jp">pr@chugai-pharm.co.jp</a></td>
</tr>
<tr>
<td>Tomoko Shimizu, Hiroshi Araki, Chisato Miyoshi, Yayoi Yamada, Shumpei Yokoyama</td>
<td></td>
</tr>
</tbody>
</table>

## Investor Relations Group

<table>
<thead>
<tr>
<th>Tel:</th>
<th>+81 (0)3-3273-0554</th>
</tr>
</thead>
<tbody>
<tr>
<td>E-mail:</td>
<td><a href="mailto:ir@chugai-pharm.co.jp">ir@chugai-pharm.co.jp</a></td>
</tr>
<tr>
<td>Toshiya Sasai, Takayuki Sakurai, Tomoyuki Shimamura, Sachiyo Yoshimura</td>
<td></td>
</tr>
</tbody>
</table>